{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T04:25:28Z","timestamp":1758860728503},"reference-count":72,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplantation Reviews"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.trre.2010.11.001","type":"journal-article","created":{"date-parts":[[2011,6,29]],"date-time":"2011-06-29T23:53:54Z","timestamp":1309391634000},"page":"145-153","source":"Crossref","is-referenced-by-count":8,"title":["Targeting the dysregulated mammalian target of rapamycin pathway in organ transplantation: killing 2 birds with 1 stone"],"prefix":"10.1016","volume":"25","author":[{"given":"Michael","family":"Haidinger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Werzowa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Weichhart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus D.","family":"S\u00e4emann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.trre.2010.11.001_bb0005","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1042\/0264-6021:3460561","article-title":"The PI3K-PDK1 connection: more than just a road to PKB","volume":"346","author":"Vanhaesebroeck","year":"2000","journal-title":"Biochem J"},{"key":"10.1016\/j.trre.2010.11.001_bb0010","doi-asserted-by":"crossref","first-page":"40406","DOI":"10.1074\/jbc.M508361200","article-title":"mTOR.RICTOR is the Ser473 kinase for Akt\/protein kinase B in 3T3-L1 adipocytes","volume":"280","author":"Hresko","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.trre.2010.11.001_bb0015","doi-asserted-by":"crossref","first-page":"4715","DOI":"10.1021\/ja043277y","article-title":"Characterization of the FKBP.rapamycin.FRB ternary complex","volume":"127","author":"Banaszynski","year":"2005","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.trre.2010.11.001_bb0020","first-page":"31","article-title":"Effects of biologically active pectin-containing dietary supplement on gastroduodenal motility in patients with a functional dyspepsia","volume":"71","author":"Loranskaia","year":"2002","journal-title":"Vopr Pitan"},{"key":"10.1016\/j.trre.2010.11.001_bb0025","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.cell.2006.08.033","article-title":"SIN1\/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity","volume":"127","author":"Jacinto","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.trre.2010.11.001_bb0030","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.it.2009.02.002","article-title":"The multiple facets of mTOR in immunity","volume":"30","author":"Weichhart","year":"2009","journal-title":"Trends Immunol"},{"key":"10.1016\/j.trre.2010.11.001_bb0035","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/ncb839","article-title":"TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling","volume":"4","author":"Inoki","year":"2002","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.trre.2010.11.001_bb0040","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.immuni.2008.08.012","article-title":"The TSC-mTOR signaling pathway regulates the innate inflammatory response","volume":"29","author":"Weichhart","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.trre.2010.11.001_bb0045","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.cell.2006.06.055","article-title":"TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth","volume":"126","author":"Inoki","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.trre.2010.11.001_bb0050","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/13813450902988580","article-title":"PRAS40: target or modulator of mTORC1 signalling and insulin action?","volume":"115","author":"Nascimento","year":"2009","journal-title":"Arch Physiol Biochem"},{"key":"10.1016\/j.trre.2010.11.001_bb0055","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1172\/JCI29092","article-title":"Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions","volume":"116","author":"Yang","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.trre.2010.11.001_bb0060","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.molcel.2006.03.029","article-title":"Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt\/PKB","volume":"22","author":"Sarbassov","year":"2006","journal-title":"Mol Cell"},{"key":"10.1016\/j.trre.2010.11.001_bb0065","doi-asserted-by":"crossref","first-page":"403","DOI":"10.4161\/cc.8.3.7555","article-title":"PI3K\/mTORC1 activation in hamartoma syndromes: therapeutic prospects","volume":"8","author":"Krymskaya","year":"2009","journal-title":"Cell Cycle"},{"key":"10.1016\/j.trre.2010.11.001_bb0070","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/ng1494","article-title":"Dysregulation of the TSC-mTOR pathway in human disease","volume":"37","author":"Inoki","year":"2005","journal-title":"Nat Genet"},{"key":"10.1016\/j.trre.2010.11.001_bb0075","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1042\/BST0370259","article-title":"Therapeutic targeting of mTOR in tuberous sclerosis","volume":"37","author":"Sampson","year":"2009","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.trre.2010.11.001_bb0080","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/S0140-6736(03)13044-9","article-title":"Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma","volume":"361","author":"El-Hashemite","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.trre.2010.11.001_bb0085","first-page":"400","article-title":"Allelic loss is frequent in tuberous sclerosis kidney lesions but rare in brain lesions","volume":"59","author":"Henske","year":"1996","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.trre.2010.11.001_bb0090","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1177\/088307389801301206","article-title":"Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria","volume":"13","author":"Roach","year":"1998","journal-title":"J Child Neurol"},{"key":"10.1016\/j.trre.2010.11.001_bb0095","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(08)61279-9","article-title":"Tuberous sclerosis","volume":"372","author":"Curatolo","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.trre.2010.11.001_bb0100","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/jmg.33.6.480","article-title":"A cross sectional study of renal involvement in tuberous sclerosis","volume":"33","author":"Cook","year":"1996","journal-title":"J Med Genet"},{"key":"10.1016\/j.trre.2010.11.001_bb0105","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1440-1797.2005.00425.x","article-title":"Huge renal angiomyolipomas in tuberous sclerosis complex","volume":"10","author":"Chan","year":"2005","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.trre.2010.11.001_bb0110","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000182439","article-title":"Chronic renal failure in patients with tuberous sclerosis. Association with renal cysts","volume":"30","author":"Okada","year":"1982","journal-title":"Nephron"},{"key":"10.1016\/j.trre.2010.11.001_bb0115","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1093\/oxfordjournals.ndt.a027315","article-title":"Chronic renal failure and its treatment in tuberous sclerosis","volume":"11","author":"Schillinger","year":"1996","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2010.11.001_bb0120","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1093\/ndt\/14.4.988","article-title":"End-stage renal failure in adults with the tuberous sclerosis complex","volume":"14","author":"Clarke","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2010.11.001_bb0125","first-page":"349","article-title":"Tuberous sclerosis complex with end-stage renal failure","volume":"10","author":"Neumann","year":"1995","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2010.11.001_bb0130","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S0025-6196(12)61196-3","article-title":"Causes of death in patients with tuberous sclerosis","volume":"66","author":"Shepherd","year":"1991","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.trre.2010.11.001_bb0135","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1528-1167.2007.01035.x","article-title":"Tuberous sclerosis complex and epilepsy: recent developments and future challenges","volume":"48","author":"Holmes","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.trre.2010.11.001_bb0140","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00408-008-9087-5","article-title":"Lymphangioleiomyomatosis and tuberous sclerosis complex","volume":"186","author":"Chorianopoulos","year":"2008","journal-title":"Lung"},{"key":"10.1016\/j.trre.2010.11.001_bb0145","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1378\/chest.07-0898","article-title":"Lymphangioleiomyomatosis: a clinical update","volume":"133","author":"McCormack","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.trre.2010.11.001_bb0150","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1038\/ejhg.2008.162","article-title":"PTEN hamartoma tumor syndromes","volume":"16","author":"Blumenthal","year":"2008","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.trre.2010.11.001_bb0155","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/978-1-4419-6448-9_22","article-title":"Von Hippel Lindau syndrome","volume":"685","author":"Kim","year":"2010","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.trre.2010.11.001_bb0160","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1093\/hmg\/ddi190","article-title":"A mouse model of tuberous sclerosis 1 showing background specific early post-natal mortality and metastatic renal cell carcinoma","volume":"14","author":"Wilson","year":"2005","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.trre.2010.11.001_bb0165","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1203\/01.PDR.0000147727.78571.07","article-title":"Effects of rapamycin in the Eker rat model of tuberous sclerosis complex","volume":"57","author":"Kenerson","year":"2005","journal-title":"Pediatr Res"},{"key":"10.1016\/j.trre.2010.11.001_bb0170","first-page":"5645","article-title":"Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors","volume":"62","author":"Kenerson","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.trre.2010.11.001_bb0175","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/gcc.20118","article-title":"Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models","volume":"42","author":"Lee","year":"2005","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.trre.2010.11.001_bb0180","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ana.21331","article-title":"Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex","volume":"63","author":"Zeng","year":"2008","journal-title":"Ann Neurol"},{"key":"10.1016\/j.trre.2010.11.001_bb0185","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1242\/dmm.002386","article-title":"Rapamycin suppresses seizures and neuronal hypertrophy in a mouse model of cortical dysplasia","volume":"2","author":"Ljungberg","year":"2009","journal-title":"Dis Model Mech"},{"key":"10.1016\/j.trre.2010.11.001_bb0190","doi-asserted-by":"crossref","first-page":"10320","DOI":"10.1073\/pnas.171060098","article-title":"An inhibitor of mTOR reduces neoplasia and normalizes p70\/S6 kinase activity in Pten+\/\u2212 mice","volume":"98","author":"Podsypanina","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.trre.2010.11.001_bb0195","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1111\/j.0013-9580.2004.23004.x","article-title":"Abnormal cortical cells and astrocytomas in the Eker rat model of tuberous sclerosis complex","volume":"45","author":"Takahashi","year":"2004","journal-title":"Epilepsia"},{"key":"10.1016\/j.trre.2010.11.001_bb0200","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa063564","article-title":"Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis","volume":"358","author":"Bissler","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2010.11.001_bb0205","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1056\/NEJMc072500","article-title":"Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis","volume":"358","author":"Davies","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2010.11.001_bb0210","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ejim.2006.07.017","article-title":"Dramatic effect of sirolimus on renal angiomyolipomas in a patient with tuberous sclerosis complex","volume":"18","author":"Herry","year":"2007","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.trre.2010.11.001_bb0215","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1053\/j.ajkd.2006.05.018","article-title":"Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex","volume":"48","author":"Wienecke","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.trre.2010.11.001_bb0220","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1136\/adc.2009.159210","article-title":"Sirolimus and tuberous sclerosis-associated renal angiomyolipomas","volume":"95","author":"Krischock","year":"2010","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.trre.2010.11.001_bb0225","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.2169\/internalmedicine.48.2411","article-title":"Malignant epithelioid angiomyolipoma in the kidney and liver of a patient with pulmonary lymphangioleiomyomatosis: lack of response to sirolimus","volume":"48","author":"Higa","year":"2009","journal-title":"Intern Med"},{"key":"10.1016\/j.trre.2010.11.001_bb0230","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1200\/JCO.2009.26.3061","article-title":"Sirolimus and temsirolimus for epithelioid angiomyolipoma","volume":"28","author":"Wolff","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.trre.2010.11.001_bb0235","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.trre.2010.11.001_bb0240","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1200\/JCO.2006.10.5916","article-title":"Phase I\/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma","volume":"25","author":"Motzer","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.trre.2010.11.001_bb0245","first-page":"6566","article-title":"Sirolimus therapy for fibromatosis and multifocal renal cell carcinoma in a child with tuberous sclerosis complex","volume":"70","author":"Pressey","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.trre.2010.11.001_bb0250","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1177\/08830738050200040901","article-title":"Intractable seizures in tuberous sclerosis complex: from molecular pathogenesis to the rationale for treatment","volume":"20","author":"Curatolo","year":"2005","journal-title":"J Child Neurol"},{"key":"10.1016\/j.trre.2010.11.001_bb0255","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/ana.20784","article-title":"Rapamycin causes regression of astrocytomas in tuberous sclerosis complex","volume":"59","author":"Franz","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1016\/j.trre.2010.11.001_bb0260","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1177\/0883073808321764","article-title":"Regression of subependymal giant cell astrocytoma with rapamycin in tuberous sclerosis complex","volume":"23","author":"Koenig","year":"2008","journal-title":"J Child Neurol"},{"key":"10.1016\/j.trre.2010.11.001_bb0265","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/pbc.22298","article-title":"Rapamycin (sirolimus) in tuberous sclerosis associated pediatric central nervous system tumors","volume":"54","author":"Lam","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.trre.2010.11.001_bb0270","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.pediatrneurol.2010.01.016","article-title":"Optic nerve tumor in tuberous sclerosis complex is not responsive to sirolimus","volume":"42","author":"Sparagana","year":"2010","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.trre.2010.11.001_bb0275","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1177\/0883073808324535","article-title":"Rapamycin reduces seizure frequency in tuberous sclerosis complex","volume":"24","author":"Muncy","year":"2009","journal-title":"J Child Neurol"},{"key":"10.1016\/j.trre.2010.11.001_bb0280","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/ncponc1112","article-title":"Rapamycin treatment for a child with germline PTEN mutation","volume":"5","author":"Marsh","year":"2008","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.trre.2010.11.001_bb0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.healun.2008.09.014","article-title":"Lung transplantation for lymphangioleiomyomatosis: the European experience","volume":"28","author":"Benden","year":"2009","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2010.11.001_bb0290","first-page":"1385","article-title":"Sirolimus in renal transplant recipients with tuberous sclerosis complex: clinical effectiveness and implications for innate immunity","volume":"89","author":"Haidinger","year":"2010","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2010.11.001_bb0295","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1016\/j.transproceed.2009.06.227","article-title":"Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex","volume":"41","author":"Tarasewicz","year":"2009","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2010.11.001_bb0300","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1365-2133.2008.08677.x","article-title":"The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis","volume":"159","author":"Hofbauer","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.trre.2010.11.001_bb0305","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1183\/09031936.06.00113303","article-title":"Lymphangioleiomyomatosis","volume":"27","author":"Johnson","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.trre.2010.11.001_bb0310","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMc086040","article-title":"Sirolimus for lymphangioleiomyomatosis lesions","volume":"358","author":"Egan","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2010.11.001_bb0315","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.healun.2008.05.012","article-title":"Sirolimus amelioration of clinical symptoms of recurrent lymphangioleiomyomatosis after living-donor lobar lung transplantation","volume":"27","author":"Sugimoto","year":"2008","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2010.11.001_bb0320","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1016\/j.athoracsur.2008.07.107","article-title":"Sirolimus treatment for recurrent lymphangioleiomyomatosis after lung transplantation","volume":"87","author":"Chen","year":"2009","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.trre.2010.11.001_bb0325","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.athoracsur.2008.07.062","article-title":"Sirolimus ameliorated post lung transplant chylothorax in lymphangioleiomyomatosis","volume":"86","author":"Ohara","year":"2008","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.trre.2010.11.001_bb0330","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.healun.2008.01.005","article-title":"Regression of pulmonary lymphangioleiomyomatosis (PLAM)-associated retroperitoneal angiomyolipoma post-lung transplantation with rapamycin treatment","volume":"27","author":"Morton","year":"2008","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2010.11.001_bb0335","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1016\/j.transproceed.2008.08.086","article-title":"Conversion to rapamycin in a renal transplant patient with von Hippel-Lindau disease: encouraging results\u2014a case report","volume":"40","author":"Henriquez","year":"2008","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2010.11.001_bb0340","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.tibs.2004.11.003","article-title":"Restraining PI3K: mTOR signalling goes back to the membrane","volume":"30","author":"Harrington","year":"2005","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.trre.2010.11.001_bb0345","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1158\/1078-0432.CCR-09-3022","article-title":"The efficacy of the novel dual PI3-kinase\/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma","volume":"16","author":"Cho","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.trre.2010.11.001_bb0350","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1158\/0008-5472.CAN-09-4355","article-title":"Drugging the PI3 kinome: from chemical tools to drugs in the clinic","volume":"70","author":"Workman","year":"2010","journal-title":"Cancer Res"},{"issue":"Suppl 3","key":"10.1016\/j.trre.2010.11.001_bb0355","doi-asserted-by":"crossref","first-page":"iii70","DOI":"10.1136\/ard.2008.098459","article-title":"The PI3K\/Akt\/mTOR pathway in innate immune cells: emerging therapeutic applications","volume":"67","author":"Weichhart","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.trre.2010.11.001_bb0360","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nm.2091","article-title":"Effective and selective targeting of leukemia cells using a TORC1\/2 kinase inhibitor","volume":"16","author":"Janes","year":"2010","journal-title":"Nat Med"}],"container-title":["Transplantation Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X11000061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X11000061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T14:39:00Z","timestamp":1560350340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0955470X11000061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":72,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0955470X11000061"],"URL":"https:\/\/doi.org\/10.1016\/j.trre.2010.11.001","relation":{},"ISSN":["0955-470X"],"issn-type":[{"value":"0955-470X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}